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ABSTRACT - Objective: To investigate the association between total plasma homocysteine concentration,
C677T and A1298C polymorphisms in MTHFR gene and Alzheimer´s disease (AD) development. M e t h o d :
F o rt y - t h ree patients with probable (63%) and possible (37%) AD and 50 non-demented controls were eval-
uated. Groups did not differ as to gender, age, scholar years, diabetes, alcohol and coffee intake and phys-
ical activity. Total plasma homocysteine (Hcy) levels were determined by HPLC and genotyping for MTHFR
by PCR/RFLP. Mann-Whitney “U” test was used to compare quantitative variable, Fisher- F re e m a n - H a l t o n
test to compare genotypes and allele pro p o rtions and Chi-square test to other qualitative variables. R e s u l t s :
AD patients presented higher total plasma Hcy levels than controls and the diff e rence was statistically sig-
nificant. No diff e rences in the C677T and A1298C MTHFR polymorphisms distributions were found between
patients and controls. Plasma homocysteine concentration did not change with MTHFR genotypes.
Conclusion: Our data confirms the association between increased plasma Hcy concentration and AD and
suggests that neither C677T nor A1298C MTHFR polymorphisms contributed to genetic susceptibility for
AD in elderly individuals in the Northeast of Brazil.
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A doença de Alzheimer em idosos brasileiros tem relação com homocisteina mas não com poli-
morfismos MTHFR
RESUMO - Objetivo: Investigar a associação entre a concentração plasmática total de homocisteína (Hcy),
os polimorfismos C677T e A1298C do gene MTHFR e o desenvolvimento da Doença de Alzheimer (AD).
Método: Foram avaliados 43 pacientes com doença de Alzheimer possível (37%) e provável (63%) e 50 con-
t roles não dementes, não divergentes quanto ao sexo, idade, anos de escolaridade, diabetes, consumo de
álcool e de café e vida sedentária. Os níveis plasmáticos de homocisteína foram determinados por HPLC e
a genotipagem para MTHFR por PCR/RFLP. A comparação dos níveis de homocisteína foi realizada pelo
teste “U” Mann-Whitney, a comparação das proporções dos genótipos e alelos pelo teste de Fisher- F re e m a n -
Halton e as demais variáveis qualitativas, pelo teste do qui-quadrado. Resultados: Os pacientes AD apre-
sentaram níveis mais elevados de Hcy plamática total do que os controles e a diferença entre os grupos foi
estatisticamente significante. Não houve diferença nas distribuições genotípicas C677T e A1298C entre
pacientes e controles. A concentração de Hcy não variou com os genótipos. Conclusão: Nossos dados con-
f i rmam a associação de concentração elevada de Hcy plasmática com DA e sugerem que os polimorf i s m o s
C677T e A1209C não contribuem para a susceptibilidade genética a DA em idosos do Nordeste do Brasil.
PALAVRAS-CHAVE: homocisteína, MTHFR, doença de Alzheimer.
M e t i l e n e t e t r a i d rofolate reductase (MTHFR) is an
enzyme of the folate metabolism that reduces 5,10-
m e t i l e n e t e t r a i d rofolate (5,10-mTHFR) to 5-metilte-
t r a i d rofolate (5-mTHF), an important co-factor to
homocysteine (Hcy) methylation. Mutations in MTH-
FR gene (C677T and A1298C) result in aminoacids
substitutions that lead to a decreased enzyme activ-
i t y, reducing the 5mTHF availability1 , 2. These muta-
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tions have got polymorphic pro p o rtions in human
p o p u l a t i o n s3. As a consequence of the MTHFR dys-
functions, an increased Hcy level in plasma has been
expected which, in turn, produces a cytotoxic eff e c t4.
Hcy belongs to a thiol group and it might pro d u c e
self-oxidations resulting in oxygen specimens such as
h y d rogen peroxide and radical anionic supero x i d e s ,
probably responsible for cerebral oxidative stress in
Alzheimer´s disease (AD) and other neuro d e g e n e r a-
tive disord e r s5. AD patients have brain atrophy char-
acterized by neuro f i b r i l l a rrytangles, senile plaques
and neuronal cell loss. Neuro f i b r i l l a ry tangles are in-
soluble phosphorylated helical filaments (PHF) de-
posits which derive from tau protein hyperphospho-
rylated that lost pro p e rty to polymerise tubulin6. The
ru p t u res in cytoskeleton derived from these alter-
ations contribute to neuronal death7. Senile plaques
a re extracellular deposits of -amyloid material made
f rom proteolytic fragments of a larger pre c u r s o r, the
-amyloid precursor protein (APP)8.
Epidemiological studies have re p o rted an associ-
ation between increased plasma Hcy level and AD9 , 1 0
and indicate a relationship between hyperh o m o c y s-
teinemia and MTHFR polymorphisms or between ho-
mozygous genotype 677TT and DA1 1 , 1 2. Researches in
AD which use animal models have demonstrated that
folate deficiency and higher level Hcy increase sen-
sibility to -amyloid toxicity in neurons, PHF and hy-
perphosphorilated tau protein deposits and apopto-
s i s1 3. In spite of these evidences, contradictory data
in the literature indicate that the role of elevated
Hcy and MTHFR polymorphisms as contributors fac-
tors to the etiopathogenesis of the disease re m a i n s
unclear14-16.
H y p e rhomocysteinemia such as in AD result fro m
a complex interaction of acquired and genetic fac-
tors which may vary according to ethnicity, enviro n-
mental factors and genetic background. So, this study
was carried out to investigate if C677T and A1298C
MTHFR polymorphisms as well as increased plasma
Hcy level play as risk factors to AD in elderly individ-
uals in the Northeast of Brazil.
METHOD
Subjects – The studied group consisted of 42 individu-
als (7 males and 35 females) of which, 69% were white peo-
ple, with ages ranging from 56 to 86 years (mean age 73.8
years, SD=7.2). Of these total, 63% were probable AD and
37% possible AD, accordin g to NINCDS-ADRDA criteria1 7.
Patients were selected from the Behavorial Neuro b i o l o g y
Unit - Department of Neurology - University of Pern a m b u c o
(Brazil). The control group consisted of 50 individuals (13
males and 37 females) of which 40% were white people,
aged 61-89 (mean age 73.9; SD=6.5). They were selected in
the community to which the University belongs. Individuals
who had undergone vitamin or hormonal therapy were
bedridden or had hyperthension were excluded from the
study.
Although Brazil is a racial melting pot and the assign-
ment of race, a very subjective issue in this country, patients
and controls were classified as non- white (40%), just by
visual inspection, w henever traces of racial mixture were
evident. Individuals had diff e rent pro p o rtions of white,
black and indigen blood.
Data re g a rding formal education, family history of de-
mentia, diabetes, smoking habit, alcohol intake and no
physical activity were collected through interviews.
This study was approved by the Ethnics Committee of
the State University of Pernambuco and a written consent
was obtained from every individuals participating in the
study.
Plasmatic homocysteine and genotyping – Total Hcy
concentrations in plasma were measured by HPLC with flu-
o rescence detection. Pro c e d u res for the sample pre p a r a-
tion were reported by Pfiffer et al.18. DNA was isolated by
using a Wi z a rd Genomic DNA Purification kit (Pro m e g a )
and the genotyping protocols for detection of the MTHFR
mutations were the ones described by Frosst et al.1 9 f o r
C677T and by Skibola et al.20 for A1298C.
Statistical analysis – P revious to statistical analysis pro p-
e r, data were tested for normality (Kolmogoro v - S m i rn o v
test). Since distributions failed to meet this criterion, Mann-
Whitney “U” test was used to compare groups as to quan-
titative variable; Fisher- F reeman-Halton test to compare
genotype and allele pro p o rtions; Chi-square test to other
qualitative variables. Null hypothesis was rejected when
p<0.05. The Minitab 3.0 and Stat Exact Statistical software s
were employed for data processing.
RESULTS
Table 1 illustrates the biosocial-demographic data
collected and only race/color, family history of demen-
tia and smoking habits showed significant diff e re n c e s
between AD and control. Since some these features
a re recognized as risk factors for vascular diseases2 1
and possible AD has vascular components, we decid-
ed to compare possible and probable AD and did not
find differences between them except in family his-
t o ry(probable AD, 55%; possible AD, 7.7%; p=0.002).
Because there were no statistical diff e rences as to
other factors, possible and probable AD patients were
analyzed together.
The frequencies of the MTHFR genotypes for both
loci C677T and A1298C and respective alleles are
shown in Table 2. The distributions of the MTHFR ge-
notypes correspond to those expected by Hard y -
Weinberg equilibrium in both AD patients and con-
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Table 1. Bio-social demographic and clinical data of DA patients and controls.
Variable Patients Controls p
(N=42) (N=50) Pac x Control
Sex F,% 83 74 0.2797
Age, mean (DP) 73.8 (SD7.2) 73.9 (SD6.5) 0.6664
Colour, white,% 69 40 0.0101*
Scholar years 0-8,years,% 50 64 0.1759
Dementia familial history,% 40 6 0.0002*
Diabetes,+, % 7 6 0.8250
Smoking habits,+,% 5 24 0.0234*
Alcohol intake, + % 9.5 18 0.2450
Sedentarism, +, % 76.2 60 0.0989
Qualitative variable, by chi-square test and quantitative variable, by Mann-Whitney “U” test. *Statistically
significant.
Table 2. Distribution of AD patients and controls according to MTHFR genotypes
and alleles proportions.
Genotypes AD Patients Control p
and alleles N (43) % N (50) %
C677T
CC 19 44.2 25 50.0
CT 19 44.2 23 46.0 0.43
TT 5 11.6 2 4.0
Allele 677T 29 34.0 27 27.0 0.31
A1298C
AA 21 48.8 27 54.0
AC 21 48.8 22 44.0 0.84
CC 1 2.4 1 2.0
Allele 1298C 23 27.0 24 24.0 0.66
Fisher-Freemann-Halton test
Table 3. Homocysteine levels in AD patients and controls according MTH -
FR genotypes.
Genotypes AD patients Control p
(N=43) (N=50)
X±SD X±SD
C677T
CC 18.98±10.2 15.57±6.3 0.22
CT 16.89±4.3 14.50±3.9 0.08
TT 21.29±5.8 22.30±– –
A1298C
AA 18.66±7.0 15.11±4.9 0.03
AC 10.00±8.5 15.49±6.9 0.16
CC 17.64±– 18.25±– –
Total 18.31±7.6 15.34±75.4 0.02
Comparisons: Mann-Whitney  “U” test.
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t rols, indicating that the allelic combinations were
made casually. Although the 677TT homozygous fre-
quency was higher in patients (11.6%) than in con-
t rols (677TT=4%), as expected, the diff e rence in geno-
types distribution was not significant (p>0.05). No
statistical diff e rences were observed in A1298C geno-
types and alleles, either (p>0.05). 
Considering that allelic frequencies vary with eth-
n i c i t y, white and non-white individuals were exam-
ined as to the proportions of genotypes and alleles.
Genotype carriers of mutant allele 677T (TT+CT), in
relation to 677CC genotype had higher pre v a l e n c e
in white patients (p=0.014). Controls did not pre s e n t
this relation (p=0.77). Allele pro p o rtions in white and
non-white people were not statistically diff e rent (pa-
tients, p=0.078; controls, p=0.713).
Hcy concentration was analyzed according to gen-
d e r, race/colour and age. Males presented the most
i n c reased Hcy concentrations in both patients (M=
2 3 . 2 3±8.01; F=17.52±7.30; p=0.004) and control gro u p
( M = 1 9 . 7 3±7.71; F=13.80±3.35; p=0.0010). No diff e r-
ence between white and non-whites was observed.
The level of total plasma homocysteine was signi-
ficantly higher in AD patients (18.3 µM/L ± 7.6) than
in controls (15.3 µM/L ± 5.4; p=0.02). Hcy was also
analyzed according to MTHFR genotypes distribu-
tions (Table 3). No significant increase in Hcy level as
was theoretically supposed for both 677TT and
1298CC people were observed. An unexpected in-
c rease on Hcy level was observed in 1298AA (p=0.03).
DISCUSSION
Of the several biosocial-demographic feature s
analyzed in this study, only ethnic origin (white/non-
white), dementia family history and smoking habit
w e re statistically diff e rent in AD patients and con-
trols. Smoking habit is an adquired factor which in-
c reases the susceptibility for vascular diseases but dif-
f e rence between them could not be attributed to
subtypes of AD because probable and possible AD
w e re not diff e rent as to the prevalence of smokers
and controls had more smokers than patients. It has
been stablished that high values of homocysteine
and AD result from the interaction of adquired and
genetic factors. 
T h e re is considerable epidemiologic evidence of
i n c reased plasma Hcy levels in elderly people, whether
n o rmal or cognitively impairs2 2 , 2 3, including AD1 7 , 2 4.
In this communication, we present data support i n g
the association between Hcy plasmatic concentration
and AD. According Postiglione et al.2 5 h y p e rh o m o-
cysteinemia is related to the pro g ression and incre a s-
ing severity of AD. Because inadequate blood levels
of folate, B12 and B6 vitamins are responsible for
a p p roximately two-thirds of the hyperh o m o c y s t e i n e-
mia cases26, the bad nutritional status which accom-
panies the pro g ressive severity and long duration of
AD would, perhaps explain a great number of AD
patients with increased Hcy level.
G e n e t i c a l l y, we studied the contribution of the
polymorphisms C677T and A1298C of the MTHFR
gene in plasma concentration of Hcy and in the devel-
opment of AD, since this enzyme is involved in Hcy
metabolism.
The mutation of C677T in MTHFR gene pro d u c e s
an enzyme which has a catalytic activity of 30% and
40% in carriers of TT and CT genotypes, re s p e c t i v e-
l y, as compared with CC genotype2 7. In A1298C MTH-
FR polymorphisms, although the enzyme is not a ther-
molabile protein, the catalytic activity is also short-
er among homozygous CC. Enzymatic deficiency may
result from MTHFR polymorphisms and develop AD
and hyperhomocysteinemia, but our data did not
c o n f i rmthis hypothesis because no significant diff e r-
ence was observed in genotypes distributions and
alleles frequencies between our AD patients and con-
trols.
Because the mixing of white and blacks is more
intense in the North and in the Northeast of Brazil
(white 29%; non-white 71%) than in other re g i o n s
of the country and also because genotypes may dif-
fer according to ethnicity, the individuals in the two
g roups were also compared as to race/color. The pro-
p o rtion of CT+TT was significantly higher in white
AD patients (72%) than in non-white (~31%; p = 0 . 0 1 4 ) .
Scientific literature shows that, in fact, the short e s t
677TT genotype frequencies are among blacks2 8 , 2 9.
However, data failed in confirming the same results
for controls, maybe due to the smaller pro p o rtion of
whites in the control group.
In the population from Pernambuco (n= 42 pa-
tients; n=50 controls) 677T allele frequencies were
37% in patients and 27% in controls. In the popula-
tion from Rio Grande do Sul (n=30 patients; n=30
c o n t rols), a south Brazilian State where Caucasians
a re more fre q u e n t3 0, 677T allele frequencies were
35% in patients and 29% in controls. There was no
statistically significant diff e rence between both pop-
ulations. We suppose that a study involving a bigger
sample and a better definition of ethnic origin by
molecular markers might account for these contra-
dictories data. 
We could not associate MTHFR genotypes with
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Hcy, except in 1298AA individuals. Although higher
male/female relation may explain some elevated Hcy
concentration in controls, 677T allele seems to con-
tribute for this result. In order to test this supposi-
tion we excluded 1298AA individuals who were 677TT
simultaneously from the data and then, the means
w e rediminished and the diff e rence between patients
(15.25 µM/L ± 4.47) and controls (14.54 µM/L ± 3.51)
became insignificant (p=0.66). 
Our results are in agreement with similar studies
in Sweden31, in UK32, in Italy14,15 but association bet-
ween Hcy and AD is not consensual even in other
European and American populations4,33.
Taking all the above mentioned into considera-
tion, it is possible that others genetic factors involv-
ing Hcy metabolism, as mutations on metionina sin-
tase, folate receptor among others, have stro n g e r
e ffect on AD and Hcy than MTHFR loci. Enviro n-
mental factors such as nutritional deficiency of folate,
vitamin B6 and B12 may also contribute to incre a s e
the Hcy levels in AD patients as such genetic factors.
As limitations of this study, we can point out the
small size of the sample, particularly the number of
white people in the control group and the failure to
evaluate the nutritional status of patients and con-
t rols by determining concentrations of folate, B6 and
B12 vitamins in plasma. Our data confirm the asso-
ciation between plasma Hcy level and AD and sug-
gest that C677T and A1298C MTHFR polymorphisms
do not contribute to genetic susceptibility for
Alzheimer´s disease in elderly individuals in the nort h-
east of Brazil. 
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